| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/05/2004 | US20040024206 Pyrimidine compounds |
| 02/05/2004 | US20040024203 Imines such as 4-(3-((3-(2,4-dichlorophenyl)propanoyl)amino)-1-(3-(morpholin-4-yl)propyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-5-yl)benzamide, administered for prophylaxis of Alzheimer's disease |
| 02/05/2004 | US20040024199 Comprises heteropolypolysaccharide composed of alternating straight and branched portions consisting of partially acetylated and methylated galacturonic acid residues linked to rhamnose, arabinose and galactose |
| 02/05/2004 | US20040024197 Synthetic oligo- and polysaccharides exhibiting at least one covalent bond with biotin or a biotin derivative and having the anticoagulant and antithrombotic pharmacological activities of heparin |
| 02/05/2004 | US20040024196 Phase transfer catalyzed glycosidation of an indolocarbazole |
| 02/05/2004 | US20040024190 Viral polymerase inhibitors |
| 02/05/2004 | US20040024066 E.g., N-(2-(Benzo(b)thiophen-5-ylmethanesulfonyl)-1-(3,4-dichloro- phenyl)- ethyl)-N-hydroxyformamide; gene expression inhibitors of s-CD23; autoimmune disease; antiallergens; matrix metalloprotease enzyme inhibitors |
| 02/05/2004 | US20040024065 Novel metabolic targets and markers |
| 02/05/2004 | US20040024064 Determining risk for developing a fat metabolism disorder by comparing a sample Gs alpha expression level with that of the normal level; treating the disorder with a nucleic acid that codes a Gs alpha protein; prognosis; diagnosis; |
| 02/05/2004 | US20040024063 Fatty acid analogues for the treatment of cancer |
| 02/05/2004 | US20040024062 Inhibiting a condition mediated by the alpha v beta 3 or alpha v beta 5 integrin; antitumor, -metastasis, -arthritic agents; angiogenesis, inhibitors; osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration |
| 02/05/2004 | US20040024061 Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and the alkanoyl l-carnitines with taurine chloride and glycine chloride |
| 02/05/2004 | US20040024060 Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 02/05/2004 | US20040024059 Novel pleuromutilin derivatives |
| 02/05/2004 | US20040024057 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications |
| 02/05/2004 | US20040024056 Especially Cryptotanshinone and Dihydortanshinone; treatment of chronic hepatitis and hepatocirrhosis |
| 02/05/2004 | US20040024055 Compounds HNP-98701A (epi-manassantin A), HNP-98701B and HNP-98701C (manassantin A) as carcinostatis substances |
| 02/05/2004 | US20040024053 Vitamin c compositions |
| 02/05/2004 | US20040024052 Processes for preparing crystalline and amorphous mupirocin calcium |
| 02/05/2004 | US20040024051 C10 heterosubstituted acetate taxanes |
| 02/05/2004 | US20040024050 Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation |
| 02/05/2004 | US20040024049 Cytotoxic agents containing novel potent taxanes and their therapeutic use |
| 02/05/2004 | US20040024048 Medicaments for treating dementia |
| 02/05/2004 | US20040024047 For treating diseases with aminothiophene inhibitors of IKK-beta phosphorylation of I kappa B, including inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease |
| 02/05/2004 | US20040024044 In chemoprevention of estrogen dependent cancer in mammals, including humans |
| 02/05/2004 | US20040024043 Administering (-)N-(-)-N phenyl canbamoyleseroline; Alzheimer's disease |
| 02/05/2004 | US20040024042 COX2 inhibition in the prevention and treatment of autosomal dominant polycystic kidney disease |
| 02/05/2004 | US20040024041 Dermal therapeutic system containing non-steroidal antiphlogistics with selective cox-2 inhibition |
| 02/05/2004 | US20040024038 GABA enhancers in the treatment of diseases relating to reduced neurosteroid activity |
| 02/05/2004 | US20040024037 Includes a colorant, a solvent and an antibiotic additive produced by binding antibiotic substance to predetermined additive via chemical reaction; improves storage stability and inhibits propagation and growth of bacteria in ink |
| 02/05/2004 | US20040024036 May take form of gel, ointment or emulsion for local administration, of transdermal patch or of film deposited by a spray, characterized in that it comprises at least one absorption promoter |
| 02/05/2004 | US20040024034 For modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus |
| 02/05/2004 | US20040024033 Cancer treatment with epothilones |
| 02/05/2004 | US20040024032 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| 02/05/2004 | US20040024031 Solvates and polymorphs of ritonavir and methods of making and using the same |
| 02/05/2004 | US20040024030 Such as 4-chloro-5-(2-phenyl-thiazol-5-yl)-2H-pyrazole-3-carboxylic acid ethyl amide; for inhibiting topoisomerases; treating bacterial infections in mammals |
| 02/05/2004 | US20040024028 Comprises gradual decreases in nicotine dosage via transdermal patch |
| 02/05/2004 | US20040024027 5(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide as pharmaceutical |
| 02/05/2004 | US20040024025 Compositions and methods for inducing cell death |
| 02/05/2004 | US20040024024 Inhibiting matrix metalloproteinase and aggrecanase activity; for treatment of strokes and neurodegenerative diseases |
| 02/05/2004 | US20040024023 1-Heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands |
| 02/05/2004 | US20040024022 Methods of use and compositions for the diagnosis and treatment of infectious disease |
| 02/05/2004 | US20040024021 Heatless separation via precipitation of diastereomeric salts with tartaric acid; improved anesthetics |
| 02/05/2004 | US20040024020 Biocidal agents and methods of use |
| 02/05/2004 | US20040024018 Sustained-release preparations of quinolone antibiotics and method for preparation thereof |
| 02/05/2004 | US20040024017 Process for producing carbostyril derivatives |
| 02/05/2004 | US20040024016 Drug for prevention and/or therapy of endometriosis |
| 02/05/2004 | US20040024015 Enhancing chemotherapy/radition therapy; endothelial growth factors; side effects reduction |
| 02/05/2004 | US20040024014 Such as 2-(nitrooxy)ethyl-2-(((3-methyl-4-(2,2,2-trifluoro-ethoxy)-2 -pyridyl)methyl)sulfinyl)benzimidazolecarboxylate; kits; for treating gastrointestinal disorders/ulcers |
| 02/05/2004 | US20040024013 Medicinal compositions containing aspirin |
| 02/05/2004 | US20040024012 Crystallization/precipitation of clopidogrel-camphorsulfonic acid salts in hydrocarbon solvent; catalytic isomerizaion; for treatment of atherosclerosis |
| 02/05/2004 | US20040024011 Racemization and enantiomer separation of clopidogrel |
| 02/05/2004 | US20040024009 Dihydropyrazolo[3,4-d]thieno-[2,3-B]pyridinone inhibitors of B7-1 |
| 02/05/2004 | US20040024008 Such as N-(4-hydroxyphenyl)-3-(6-methyl-3-oxo-4-(3-(trifluoromethyl)phenyl)-3,6 -dihydrodipyrazolo(3,4-b:3,4-d)pyr idin-2(1H)-yl)benzamide for treating automimmune diseases, graft versus host disease, and multiple sclerosis |
| 02/05/2004 | US20040024007 Phosphodiesterase (pde-iv) inhibitors; respiratory system disorder treatments |
| 02/05/2004 | US20040024006 Opioid agonist analgesic, a neutral receptor binding agent and a carrier |
| 02/05/2004 | US20040024005 Methods and compositions for reducing the development of drug tolerance and/or physical dependence |
| 02/05/2004 | US20040024004 Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists |
| 02/05/2004 | US20040024003 Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy |
| 02/05/2004 | US20040024002 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity |
| 02/05/2004 | US20040024000 Dihydropyrimidine derivatives as cysteine protease inhibitors |
| 02/05/2004 | US20040023999 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 02/05/2004 | US20040023997 5-amino-pyrazolo-(4, 3-e)-1,2,4-triazolo(1,5-c)pyrimidine derivatives; treating parkinson's disease and other central nervous system disorders |
| 02/05/2004 | US20040023996 Methods and compositions utilizing quinazolinones |
| 02/05/2004 | US20040023994 Thiopurine having a sulfur heteroatom conjugated to an alpha-, beta-unsaturated carbonyl moiety and a pharmaceutical carrier |
| 02/05/2004 | US20040023992 Antiinflammatory agents |
| 02/05/2004 | US20040023991 Use of pyrazolo[4,3-d]pyrimidines |
| 02/05/2004 | US20040023990 Use of pyrazolo[4,3-d]pyrimidines |
| 02/05/2004 | US20040023989 Pyrazolo(4,3-c)piperidine and pyrazolo(4,3-d)pyrimidine derivatives |
| 02/05/2004 | US20040023988 Novel compounds |
| 02/05/2004 | US20040023987 Sustained release compositions |
| 02/05/2004 | US20040023986 Treating epilepsy, neuropathic pain, and tissue damage form ischemic events; antihypoxic agents |
| 02/05/2004 | US20040023984 Compounds for the treatment of alzheimer's disease |
| 02/05/2004 | US20040023983 Modulating metabolism by contacting with a gemifloxacin compound |
| 02/05/2004 | US20040023982 Antiviral azaindole derivatives |
| 02/05/2004 | US20040023981 Salt forms of 4-(2-(5-cyanothiazol-2-ylamino)-pyridin-4-ylmethyl) piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, |
| 02/05/2004 | US20040023980 Polymorphs with tyrosine kinase activity |
| 02/05/2004 | US20040023978 Active salt forms with tyrosine kinase activity |
| 02/05/2004 | US20040023976 Treatment of gastrointestinal stromal tumors |
| 02/05/2004 | US20040023975 Pharmaceutical compositions for the treatment of systemic inflammatory response syndrome |
| 02/05/2004 | US20040023974 Pharmacological agents which are inhibitors of PTPases, in particular, the compounds of formula I inhibit PTP-1B and TC PTP, and thus may be employed for the treatment of conditions associated with PTPase activity. The compounds of the present |
| 02/05/2004 | US20040023972 Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS |
| 02/05/2004 | US20040023971 3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias |
| 02/05/2004 | US20040023970 Method for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor in a patient in need thereof which comprises providing to said patient a therapeutically effective amount of a compound of formula I |
| 02/05/2004 | US20040023969 Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
| 02/05/2004 | US20040023967 Prevention of congestive heart failure |
| 02/05/2004 | US20040023964 7-phenylimidazo(1,2-b)(1,2,4)triazine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group which is directly attached or bridged by an oxygen atom or a |
| 02/05/2004 | US20040023963 Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| 02/05/2004 | US20040023962 Use of medicaments |
| 02/05/2004 | US20040023961 Aryl ureas with raf kinase and angiogenisis inhibiting activity |
| 02/05/2004 | US20040023960 Mammalian metabolites of the compound 2-(1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3- (4-fluoro) phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo) methylmorpholine which is a tachykinin receptor antagonist as antiemetics |
| 02/05/2004 | US20040023957 Erbb-2 selective small molecule kinase inhibitors |
| 02/05/2004 | US20040023954 Hypotensive drugs Bimatoprost, Latanaprost, Unoprostone, Travoprost and prostaglandin H2 1-ethanolamide or of structurally closely related analogs, are pro-drugs which hydrolyze under physiological conditions to provide |
| 02/05/2004 | US20040023952 Enhanced brain function by gaba-ergic stimulation |
| 02/05/2004 | US20040023951 Combination therapy comprising a first component which is a typical antipsychotic or an atypical antipsychotic and a second component which is a muscarinic agonist for the treatment of psychoses and other disorders. |
| 02/05/2004 | US20040023950 N-heterocyclic derivatives as NOS inhibitors |
| 02/05/2004 | US20040023949 Reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of- function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient |
| 02/05/2004 | US20040023948 Fast-dispersing dosage form containing 5-HT1 agonists |
| 02/05/2004 | US20040023947 Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| 02/05/2004 | US20040023946 Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines |